474 related articles for article (PubMed ID: 30550751)
21. Huntington's Disease and Mitochondria.
Jodeiri Farshbaf M; Ghaedi K
Neurotox Res; 2017 Oct; 32(3):518-529. PubMed ID: 28639241
[TBL] [Abstract][Full Text] [Related]
22. Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington's disease.
Agrawal S; Fox JH
Mitochondrion; 2019 Jul; 47():318-329. PubMed ID: 30902619
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli.
Costa V; Giacomello M; Hudec R; Lopreiato R; Ermak G; Lim D; Malorni W; Davies KJ; Carafoli E; Scorrano L
EMBO Mol Med; 2010 Dec; 2(12):490-503. PubMed ID: 21069748
[TBL] [Abstract][Full Text] [Related]
24. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease.
Rodinova M; Krizova J; Stufkova H; Bohuslavova B; Askeland G; Dosoudilova Z; Juhas S; Juhasova J; Ellederova Z; Zeman J; Eide L; Motlik J; Hansikova H
Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31278192
[TBL] [Abstract][Full Text] [Related]
25. Targeting an allosteric site in dynamin-related protein 1 to inhibit Fis1-mediated mitochondrial dysfunction.
Rios L; Pokhrel S; Li SJ; Heo G; Haileselassie B; Mochly-Rosen D
Nat Commun; 2023 Jul; 14(1):4356. PubMed ID: 37468472
[TBL] [Abstract][Full Text] [Related]
26. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
[TBL] [Abstract][Full Text] [Related]
27. Could successful (mitochondrial) networking help prevent Huntington's disease?
Oliveira JM; Lightowlers RN
EMBO Mol Med; 2010 Dec; 2(12):487-9. PubMed ID: 21117121
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington's disease R6/2 fragment model.
Hering T; Kojer K; Birth N; Hallitsch J; Taanman JW; Orth M
Exp Neurol; 2017 Feb; 288():167-175. PubMed ID: 27889468
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.
Kim J; Moody JP; Edgerly CK; Bordiuk OL; Cormier K; Smith K; Beal MF; Ferrante RJ
Hum Mol Genet; 2010 Oct; 19(20):3919-35. PubMed ID: 20660112
[TBL] [Abstract][Full Text] [Related]
30. Advanced glycation end products receptor RAGE controls myocardial dysfunction and oxidative stress in high-fat fed mice by sustaining mitochondrial dynamics and autophagy-lysosome pathway.
Yu Y; Wang L; Delguste F; Durand A; Guilbaud A; Rousselin C; Schmidt AM; Tessier F; Boulanger E; Neviere R
Free Radic Biol Med; 2017 Nov; 112():397-410. PubMed ID: 28826719
[TBL] [Abstract][Full Text] [Related]
31. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
Chiang MC; Chern Y; Huang RN
Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
[TBL] [Abstract][Full Text] [Related]
32. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
[TBL] [Abstract][Full Text] [Related]
33. Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction.
Disatnik MH; Ferreira JC; Campos JC; Gomes KS; Dourado PM; Qi X; Mochly-Rosen D
J Am Heart Assoc; 2013 Oct; 2(5):e000461. PubMed ID: 24103571
[TBL] [Abstract][Full Text] [Related]
34. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.
Yin X; Manczak M; Reddy PH
Hum Mol Genet; 2016 May; 25(9):1739-53. PubMed ID: 26908605
[TBL] [Abstract][Full Text] [Related]
35. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
36. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin.
Jin YN; Yu YV; Gundemir S; Jo C; Cui M; Tieu K; Johnson GV
PLoS One; 2013; 8(3):e57932. PubMed ID: 23469253
[TBL] [Abstract][Full Text] [Related]
37. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
38. Drp1, Mff, Fis1, and MiD51 are coordinated to mediate mitochondrial fission during UV irradiation-induced apoptosis.
Zhang Z; Liu L; Wu S; Xing D
FASEB J; 2016 Jan; 30(1):466-76. PubMed ID: 26432782
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease.
Chen CM
Chang Gung Med J; 2011; 34(2):135-52. PubMed ID: 21539755
[TBL] [Abstract][Full Text] [Related]
40. Fis1 depletion in osteoarthritis impairs chondrocyte survival and peroxisomal and lysosomal function.
Kim D; Song J; Kang Y; Park S; Kim YI; Kwak S; Lim D; Park R; Chun CH; Choe SK; Jin EJ
J Mol Med (Berl); 2016 Dec; 94(12):1373-1384. PubMed ID: 27497958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
